105 related articles for article (PubMed ID: 2142394)
21. The effect of ethynyloestradiol and medroxyprogesterone acetate on the in vivo uptake and metabolism of 3H-oestradiol by breast tumour tissue in postmenopausal women.
Reed MJ; Beranek PA; Bonney RC; Ghilchik MW; James VH
Anticancer Res; 1987; 7(6):1265-9. PubMed ID: 2831795
[TBL] [Abstract][Full Text] [Related]
22. Female sex steroid receptors in normal, hyperplastic and carcinomatous endometrium. The relationship to serum steroid hormones and gonadotropins and changes during medroxyprogesterone acetate administration.
Jänne O; Kauppila A; Kontula K; Syrjälä P; Vihko R
Int J Cancer; 1979 Nov; 24(5):545-54. PubMed ID: 231013
[No Abstract] [Full Text] [Related]
23. [Response of estrogen and progesterone receptors to treatment with large doses of progestogen (depo-provera) in endometrial cancer].
Thurzó L
Zentralbl Gynakol; 1990; 112(17):1111-5. PubMed ID: 2148245
[TBL] [Abstract][Full Text] [Related]
24. [Immunohistochemical study of the expression of receptors to steroid hormones in endometrial hyperplastic processes].
Lysenko ON; Ashkhab MKh; Strizhova NV; Babichenko II
Arkh Patol; 2004; 66(2):7-10. PubMed ID: 15154374
[TBL] [Abstract][Full Text] [Related]
25. Hormonal receptors in endometrial neoplasias.
Contreras Ortiz O; Sananes CE
Eur J Gynaecol Oncol; 1988; 9(5):396-8. PubMed ID: 2975993
[TBL] [Abstract][Full Text] [Related]
26. Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications.
Ehrlich CE; Young PC; Cleary RE
Am J Obstet Gynecol; 1981 Nov; 141(5):539-46. PubMed ID: 6457531
[TBL] [Abstract][Full Text] [Related]
27. Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium.
Minaguchi T; Nakagawa S; Takazawa Y; Nei T; Horie K; Fujiwara T; Osuga Y; Yasugi T; Kugu K; Yano T; Yoshikawa H; Taketani Y
Cancer Lett; 2007 Apr; 248(1):112-22. PubMed ID: 16919866
[TBL] [Abstract][Full Text] [Related]
28. Mouse mammary tumors induced by medroxyprogesterone acetate: immunohistochemistry and hormonal receptors.
Molinolo AA; Lanari C; Charreau EH; Sanjuan N; Pasqualini CD
J Natl Cancer Inst; 1987 Dec; 79(6):1341-50. PubMed ID: 2826865
[TBL] [Abstract][Full Text] [Related]
29. Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium.
Orejuela FJ; Ramondetta LM; Smith J; Brown J; Lemos LB; Li Y; Hollier LM
Gynecol Oncol; 2005 May; 97(2):483-8. PubMed ID: 15863148
[TBL] [Abstract][Full Text] [Related]
30. [Growth of endometrial cancer and hormone].
Kanoh H; Hosono T; Matsui Y; Okudaira Y
Gan To Kagaku Ryoho; 1989 Dec; 16(12):3696-703. PubMed ID: 2531993
[TBL] [Abstract][Full Text] [Related]
31. Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer.
van Veelen H; Willemse PH; Sleijfer DT; Sluiter WJ; Doorenbos H
Cancer Treat Rep; 1985 Sep; 69(9):977-83. PubMed ID: 3161613
[TBL] [Abstract][Full Text] [Related]
32. [Adjuvant hormone therapy in endometrial carcinoma: medroxyprogesterone acetate versus tamoxifen-medroxyprogesterone acetate sequential therapy].
Vavra N; Salzer H; Sevelda P; Breitenecker G; Czerwenka K; Kucera H
Gynakol Rundsch; 1990; 30(3):133-43. PubMed ID: 2147161
[TBL] [Abstract][Full Text] [Related]
33. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
[TBL] [Abstract][Full Text] [Related]
34. [Estrogen and progesterone receptors in endometrial carcinoma during high-dose progestogen (Depo-Provera) therapy].
Thurzó L; Sas M; Falkay G
Orv Hetil; 1986 Oct; 127(43):2613-6. PubMed ID: 2947029
[No Abstract] [Full Text] [Related]
35. Ethinyl estradiol and medroxyprogesterone acetate in patients with epithelial ovarian carcinoma: a phase II study.
Freedman RS; Saul PB; Edwards CL; Jolles CJ; Gershenson DM; Jones LA; Atkinson EN; Dana WJ
Cancer Treat Rep; 1986 Mar; 70(3):369-73. PubMed ID: 2937533
[TBL] [Abstract][Full Text] [Related]
36. Endometrial hyperplasia following estrogen treatment without the addition of gestagen. A follow-up study after withdrawal of estrogens.
Lindahl B; Willén R
Anticancer Res; 1991; 11(6):2071-3. PubMed ID: 1776842
[TBL] [Abstract][Full Text] [Related]
37. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
[TBL] [Abstract][Full Text] [Related]
38. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone.
Hargrove JT; Maxson WS; Wentz AC; Burnett LS
Obstet Gynecol; 1989 Apr; 73(4):606-12. PubMed ID: 2538787
[TBL] [Abstract][Full Text] [Related]
39. Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women.
Lobo RA; McCormick W; Singer F; Roy S
Obstet Gynecol; 1984 Jan; 63(1):1-5. PubMed ID: 6318170
[TBL] [Abstract][Full Text] [Related]
40. A randomized trial of progestogens in the primary treatment of endometrial carcinoma.
Macdonald RR; Thorogood J; Mason MK
Br J Obstet Gynaecol; 1988 Feb; 95(2):166-74. PubMed ID: 2964861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
